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The treatment of persistent symptoms attributed to Lyme disease remains controversial.
Recently, the PLEASE study did not demonstrate any additional clinical benefit of longer-
term versus shorter-term antibiotic treatment. However, the economic impact of the antibi-
otic strategies has not been investigated.
Methods
This prospective economic evaluation, adhering a societal perspective, was performed
alongside the PLEASE study, a multicenter, placebo-controlled, double-blind 1:1:1 random-
ized clinical trial in which all patients received open-label intravenous ceftriaxone for two
weeks before the 12-week randomized blinded oral antibiotic regimen (doxycycline, clari-
thromycin plus hydroxychloroquine, or placebo). Between 2010 and 2013, patients (n =
271) with borreliosis-attributed persistent symptoms were enrolled and followed for one
year. Main outcomes were costs, quality-adjusted life years, and incremental net monetary
benefit of longer-term versus shorter-term antibiotic therapy.
Results
Mean quality-adjusted life years (95% CI) were not significantly different (p = 0.96): 0.82
(0.77–0.88) for ceftriaxone/doxycycline (n = 82), 0.81 (0.76–0.88) for ceftriaxone/clarithro-
mycin-hydroxychloroquine (n = 93), and 0.81 (0.76–0.86) for ceftriaxone/placebo (n = 96).
Total societal costs per patient (95% CI) were not significantly different either (p = 0.35):







Citation: Berende A, Nieuwenhuis L, ter Hofstede
HJM, Vos FJ, Vogelaar ML, Tromp M, et al. (2018)
Cost-effectiveness of longer-term versus shorter-
term provision of antibiotics in patients with
persistent symptoms attributed to Lyme disease.
PLoS ONE 13(4): e0195260. https://doi.org/
10.1371/journal.pone.0195260
Editor: Jacobus P. van Wouwe, TNO,
NETHERLANDS
Received: November 19, 2017
Accepted: March 17, 2018
Published: April 2, 2018
Copyright: © 2018 Berende et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by a grant
(171002304) from the Netherlands Organization
for Health Research and Development (ZonMw).




€11,995 (€8,823-€15,670) for ceftriaxone/doxycycline, €12,202 (€9,572-€15,253) for ceftri-
axone/clarithromycin-hydroxychloroquine, and €15,249 (€11,294-€19,781) for ceftriaxone/
placebo. Incremental net monetary benefit (95% CI) for ceftriaxone/doxycycline compared
to ceftriaxone/placebo varied from €3,317 (-€2,199-€8,998) to €4,285 (-€6,085-€14,524)
over the willingness-to-pay range, and that of ceftriaxone/clarithromycin-hydroxychloro-
quine compared to ceftriaxone/placebo from €3,098 (-€888-€7,172) to €3,710 (-€4,254-
€11,651). For every willingness-to-pay threshold, the incremental net monetary benefits did
not significantly differ from zero.
Conclusion
The longer-term treatments were similar with regard to costs, effectiveness and cost-effec-
tiveness compared to shorter-term treatment in patients with borreliosis-attributed persistent
symptoms after one year of follow-up. Given the results of this study, and taking into account
the external costs associated with antibiotic resistance, the shorter-term treatment is the
antibiotic regimen of first choice.
Introduction
Lyme borreliosis, a tick-borne disease caused by the spirochete Borrelia burgdorferi sensu lato
complex, is the most common tick-borne disease in the northern hemisphere and its incidence
has been increasing considerably in several countries worldwide [1, 2]. Patients in the early
stages of Lyme disease can often be treated successfully with antibiotics [3, 4]. However,
regardless of initial appropriate antibiotic treatment, persistent symptoms may develop that
consist of pain, neurologic or cognitive impairments, musculoskeletal symptoms and/or
fatigue [5].
The disease burden of Lyme disease is large, and the disability-adjusted life years (DALYs)
per 100,000 population were estimated at 10.55 in 2010, resulting in 1749 DALYs for the
Dutch population [6]. Mainly persistent symptoms are a considerable source of healthcare uti-
lization and costs [6–8]. Since the incidence of Lyme disease is rising in several countries,
there are concerns that the significant economic and disease burden of persistent symptoms
attributed to Lyme disease will increase further.
The treatment of persistent symptoms attributed to Lyme disease remains controversial, as
previous trials found inconclusive results [9–11] and as clinical guidelines recommend differ-
ent treatment durations [12–14]. Recently, the Persistent Lyme Empiric Antibiotic Study
Europe (PLEASE), which evaluated the effectiveness of longer-term versus shorter-term anti-
biotic treatment among patients with borreliosis-attributed persistent symptoms, did not dem-
onstrate any additional clinical benefit of longer-term antibiotic treatment compared to
shorter-term treatment [15].
Regardless of clinical effect, it is important to assess the economic impact of the compara-
tive antibiotic strategies. This is essential for policy makers, in order to prioritize and making
complex decisions about healthcare interventions. Therefore, we performed the first cost-util-
ity analysis of longer-term versus shorter-term provision of antibiotics in patients with persis-
tent symptoms attributed to Lyme disease.
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Materials and methods
Study design and patients
This economic evaluation was performed alongside the PLEASE study, a multicenter, placebo-
controlled, double-blind randomized clinical trial, which was conducted in the Netherlands at
the Radboud university medical center and the Sint Maartenskliniek (ClinicalTrials.gov num-
ber NCT01207739). Its design and main results have been described in detail elsewhere [15,
16]. Briefly, patients were included if they experienced persistent symptoms attributed to
Lyme disease, such as pain, musculoskeletal symptoms, neuralgia, sensory disturbances, arthri-
tis, arthralgia, or neuropsychological/cognitive complaints, with or without persistent fatigue.
These symptoms had to be preceded by an erythema migrans (EM) or otherwise confirmed
symptomatic Lyme disease, or patients were required to have B. burgdorferi IgG or IgM anti-
bodies. After inclusion, patients were randomly allocated in a 1:1:1 ratio to three treatment
arms. All patients received 2000 mg open-label intravenous ceftriaxone every day for two
weeks before starting the blinded oral antibiotic regimen of 12 weeks. The randomized oral
treatment consisted of 100 mg of doxycycline twice daily combined with a placebo twice daily,
500 mg clarithromycin twice daily combined with 200 mg of hydroxychloroquine twice daily,
or two placebos twice daily. Ethical clearance of the PLEASE study protocol was obtained from
the Medical Ethics Review Committee CMO Region Arnhem-Nijmegen and all patients pro-
vided written informed consent before inclusion.
Outcome measures
The main outcome measures of the economic evaluation were costs and EQ-5D-based quality-
adjusted life years (QALYs) [17]. These outcome measures were combined into the incremen-
tal Net Monetary Benefit (NMB), adhering a societal perspective, over a one-year follow-up
period. The societal perspective includes the impact of an intervention on the welfare of the
whole of society, by including not only direct health effects (both costs and QALYs) but also
indirect health effects (such as productivity losses) [18, 19]. Outcomes were assessed at baseline
and at 14, 26, 40 and 52 weeks follow-up by self-completed questionnaires.
Effectiveness. The quality of the health status of the patients was measured with a vali-
dated health-related quality of life (HRQoL) instrument, the EuroQol-5D (EQ-5D) [20]. This
HRQoL instrument was offered in a validated Dutch translation and was completed by the
patients at all evaluation moments [17]. The EQ-5D is a generic HRQoL instrument compris-
ing five domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
The EQ-5D index is obtained by applying predetermined weights to the five domains. This
index gives a societal-based global quantification of the patient’s health status on a scale rang-
ing from zero (death) to one (perfect health). Based on the EQ-5D index scores, QALYs were
determined over the total follow-up period by using the trapezium rule to estimate the area
under the curve.
Costs. The following cost categories were considered: intervention costs, healthcare utili-
zation, pain medication utilization, travel expenses and productivity losses. Intervention costs
were standardized and, for each patient, consisted of one hospital admission day for the first
ceftriaxone administration, two weeks of outpatient treatment with ceftriaxone, 12 hours of
home care, and 12 weeks of treatment with the randomized oral regimen. The cost analysis
comprised two main parts. First, on a patient level, volumes of care were measured prospec-
tively over the time path of the clinical trial using an adapted version of the first part of the
’Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness’ (TIC-P)[21]
complemented with patient out-of-pocket expenses for pain-related over-the-counter drugs.
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Where relevant, (missing) entries were verified or completed by data from medical records.
Second, standard cost prices were determined using the Dutch guideline for cost analysis in
healthcare research [22] and www.medicijnkosten.nl, a website managed by the Dutch
National Health Care Institute, for drug prices per daily dose. If no standardized cost prices
were available, real tariffs or costs were used. Productivity losses for patients were estimated
using a patient-based questionnaire (Short Form–Health and Labor Questionnaire (SF-HLQ))
[23]. The friction cost-method was applied in accordance with the Dutch guidelines [22]. In
addition, travel expenses were computed for every healthcare visit based on the patient’s postal
code and the location of healthcare provision. Data on resource use were multiplied by stan-
dardized unit prices to calculate costs in the treatment groups. Costs were calculated in Euros
using 2015 as base-year value. Prices were indexed using the Consumer Price Index (CPI)
from Statistics Netherlands (CBS).
Data analysis
Patients who had been randomized into the study and who had received at least one dose of
ceftriaxone were included in the modified intention-to-treat analysis. If patients only com-
pleted baseline assessment, they were considered uninformative and therefore excluded from
the economic analysis. In the base-case analysis, missing data regarding QALYs and costs were
imputed with the nearest available observation as this was considered the most realistic sce-
nario. Missing data regarding time between follow-up visits were imputed a single time using
a uniform random number generator, which was limited by the minimum and maximum in
the available data.
Analyses of covariance, with paid work and baseline values as covariates, were used to com-
pare mean costs and mean QALYs gained between the three treatment groups. The cost-effec-
tiveness analysis comprised computing NMBs for each patient by multiplying the QALYs that
were gained during the one year follow-up with a range of ‘willingness-to-pay (WTP) for a
QALY’ thresholds and then subtracting the total costs from this amount. Subsequently, the
incremental NMBs were calculated by subtracting the mean NMB of the placebo group from
the mean NMBs of the longer-term treatment arms. The NMB framework, combined with
multivariable linear regression, was used to correct for relevant baseline differences (paid
work), baseline EQ-5D index score and baseline total costs. Because the cost-effectiveness
threshold in the Netherlands ranges from €10,000 to €80,000 per QALY depending on the dis-
ease burden [24, 25], six thresholds for the maximum WTP for a QALY were applied ranging
from zero to 100,000 Euros. For all regression models, 1,000 bootstrap replications were used
to account for skewness of the distribution of the estimator (NMB) in order to obtain robust
95% confidence intervals of the estimates. IBM SPSS Statistics 22.0 was used as statistical soft-
ware package.
Imputation scenario analyses. To analyze the effect of the abovementioned missing data
imputation strategy on our results, two other imputation scenarios for missing QALYs and
costs were applied in addition to the more realistic base-case nearest available observation
imputation: as a best-case scenario EQ-5D index scores were imputed with the 75th percentile
of the available data and the total costs with the 25th percentile, and as a worst-case scenario
EQ-5D index scores were imputed with the 25th percentile and total costs with the 75th percen-
tile of the available data.
Results
In total, 281 patients were enrolled into the PLEASE study between October 2010 and June
2013, and followed for one year. Of these, 271 patients were included in the cost-utility
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analysis: one patient did not start the ceftriaxone treatment; nine other patients only under-
went baseline EQ-5D assessment. Baseline characteristics were not significantly different
between the study groups, except for paid work, gaining income from the Work and Income
according to Labor Capacity Act (WIA), and travel expenses in the three months before the
start of the study (Table 1).
The average amount of QALYs yielded during the one-year follow-up period was 0.82 (95%
CI, 0.77–0.88) for the ceftriaxone plus doxycycline group, 0.81 (95% CI, 0.76–0.88) for the cef-
triaxone plus clarithromycin-hydroxychloroquine group, and 0.81 (95% CI, 0.76–0.86) for the
ceftriaxone plus placebo group. These were not significantly different between the groups
(p = 0.96). The mean total societal costs over the one-year study period were also not statistical
significantly different between the groups (p = 0.35): €11,995 (95% CI, €8,823-€15,670) for the
ceftriaxone plus doxycycline group, €12,202 (95% CI, €9,572-€15,253) for the ceftriaxone plus
clarithromycin-hydroxychloroquine group and €15,249 (95% CI, €11,294-€19,781) for the cef-
triaxone plus placebo group. The incremental total costs were plotted against the incremental
QALYs for each longer-term treatment group compared to the placebo group in Fig 1.
Antibiotic therapy, productivity losses and healthcare consumption were the main cost
drives in all study groups (Table 2). No significant differences in mean costs between the study
arms were found in any of the cost categories, although the point estimates for healthcare con-
sumption varied considerably (Table 2).
Fig 2 shows the distribution of healthcare consumption costs. As shown in Fig 2, a few out-
liers in the clarithromycin-hydroxychloroquine and placebo groups are responsible for the









Age—mean (SD) 48.6 (12.8) 48.5 (13.1) 50.2 (9.7) 0.56
Female sex–no. (%) 38 (46) 41 (44) 46 (48) 0.87
Employment statusb –no. (%)
Paid work 49 (60) 65 (70) 76 (79) 0.02
Unpaid work 7 (9) 6 (7) 7 (7) 0.87
Unemployed 4 (5) 2 (2) 2 (2) 0.47
Student 3 (4) 5 (5) 2 (2) 0.49
Housewife/man 14 (17) 15 (16) 14 (15) 0.90
General old-age insurance 11 (13) 8 (9) 8 (8) 0.46
Sickness Benefits Act 17 (21) 20 (22) 27 (28) 0.43
Labor disability (WIA) 17 (21) 15 (16) 6 (6) 0.02
EQ-5D index score–mean (SD) 0.58 (0.26) 0.59 (0.25) 0.64 (0.23) 0.22
Direct costs within healthcarec –mean (SD) 23 (39) 36 (89) 15 (26) 0.05
Pain medication (€) 7 (19) 5 (10) 6 (13) 0.68
Healthcare consumption (€) 497 (785) 1292 (5611) 582 (2074) 0.25
Direct costs outside healthcarec –mean (SD)
Travel expenses (€)
23 (39) 36 (89) 15 (26) 0.05
Indirect costsc –mean (SD) Productivity losses
(€)
2544 (5535) 1972 (4824) 2710 (4660) 0.57
Total costsc (€)–mean (SD) 3072 (5770) 3036 (7328) 3314 (5078) 0.96
a Continuous variables were compared between the groups by using an ANOVA, categorical variables by using chi-squared tests. Not normally distributed data were
analyzed with a bootstrapped ANOVA.
b Categories are not mutually exclusive.
c Baseline costs are the costs in Euros made in the three months before the start of the study. WIA, Work and Income according to Labor Capacity Act.
https://doi.org/10.1371/journal.pone.0195260.t001
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large distribution width. The outliers were mainly due to high costs of home adaptations (e.g.
placement of an elevator). Due to bootstrapping the relevance of these outliers is relatively
small and had little influence on the coefficients nor confidence intervals of the NMB regres-
sion model.
Fig 3A presents the incremental Net Monetary Benefit (iNMB) with 95% CI of both longer-
term treatment groups compared to the placebo group over the ‘willingness-to-pay (WTP)’
range from 0 to 100,000 Euros per QALY. The iNMB for the doxycycline group compared to
the placebo group varied from €3,317 (95% CI, -€2,199-€8,998) to €4,285 (95% CI, -€6,085-
€14,524) over the WTP range, and that of the clarithromycin-hydroxychloroquine group com-
pared to the placebo group from €3,098 (95% CI, -€888-€7,172) to €3,710 (95% CI, -€4,254-
€11,651). For all WTP thresholds, the iNMBs did not significantly differ from zero. The impu-
tation scenario analyses showed similar results (Fig 3B and 3C).
Fig 1. Incremental total costs plotted against incremental QALYs with 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0195260.g001




hydroxychloroquine (N = 93)
Ceftriaxone +placebo (N = 96) P valuea
Mean (95% CI) Mean (95% CI) Mean (95% CI)
QALYs 0.82 (0.77–0.88) 0.81 (0.76–0.88) 0.81 (0.76–0.86) 0.96
Direct costs within healthcare
Antibiotic therapyb 2254 (-) 2282 (-) 2211 (-) -
Pain medication 36 (23–52) 22 (16–29) 33 (22–45) 0.24
Healthcare consumption 1802 (1211–2517) 2324 (1508–3286) 3296 (1675–5521) 0.35
Direct costs outside healthcare Travel expenses 104 (66–148) 58 (39–75) 83 (51–127) 0.23
Indirect costs Productivity losses 7667 (4466–12039) 7858 (5450–10667) 9392 (6941–12270) 0.70
Total costs 11995 (8823–15670) 12202 (9572–15253) 15249 (11294–19781) 0.28
a Bootstrapped ANCOVA corrected for baseline value and paid work.
b Costs of the antibiotic therapy were standardized.
QALY, quality-adjusted life year.
https://doi.org/10.1371/journal.pone.0195260.t002
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Discussion
This study is the first economic evaluation of antibiotic therapy regimens in patients with borre-
liosis-attributed persistent symptoms, and was performed alongside the PLEASE study. We
found no differences in mean total societal costs and mean QALYs between the three groups
after a one-year study period. There was, given the range of evaluation, no willingness-to-pay
threshold for which the incremental Net Monetary Benefit of the longer-term treatment groups
compared to the placebo group was significantly different from zero. The imputation scenario
analysis also showed no significant differences in cost-effectiveness between the groups.
These results are relevant for the care of patients with persistent symptoms attributed to
Lyme disease, as they complement the effectiveness knowledge obtained from the PLEASE
study and other research. To our knowledge, no other studies have investigated the cost-utility
of antibiotic treatment regimens of persistent symptoms attributed to Lyme disease. Because
the PLEASE study did not show any additional clinical benefit of longer-term compared to
shorter-term treatment on health-related quality of life, we did not expect to find any large
differences in costs and cost-effectiveness as the oral antibiotic treatment is low-priced. Never-
theless, because of the limited resources in healthcare, cost-effectiveness of the treatment strat-
egies should be carefully considered as one of the criteria in a rational decision-making
process.
Strengths of this economic evaluation include the prospective design, in which data were
collected alongside a multicenter, placebo-controlled, double-blind randomized clinical trial.
This study was the largest trial that evaluated antibiotic therapies in patients with borreliosis-
attributed persistent symptoms. Data on health states and costs were prospectively collected
on patient-level, which made it possible to give relatively precise estimates. Moreover, we per-
formed our analyses from a societal perspective, since we included productivity losses and
travel expenses as cost categories as well. This is the optimal perspective, as it includes all rele-
vant societal costs and benefits irrespective of who bears or accrues them, and is recommended
by the Dutch guideline for economic evaluations in healthcare [22].
Fig 2. Distribution of the costs of healthcare consumption in the three treatment groups, including explanation of
the largest outliers.
https://doi.org/10.1371/journal.pone.0195260.g002
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Our study also has limitations. First, there were missing data. Missing data are almost
unavoidable in economic evaluations performed alongside a clinical trial, especially when
patients have to self-report the data and when costs and cost-effectiveness are not the primary
outcome measures. To overcome this problem and to assess the effect of our imputation strat-
egy, we imputed our data according to three scenarios. Since all scenarios gave slightly differ-
ent estimates but similar conclusions, our results are robust against assumptions regarding the
missingness of data.
Furthermore, the cause of the persistent symptoms is poorly understood. Consequently,
despite our strict inclusion criteria, it is unclear whether all symptoms in our study population
are attributable to Lyme disease. Nevertheless, this population represents the patients who are
actually encountered in clinical practice and who do suffer from low quality of life, have high
healthcare consumption and productivity losses. Therefore, research regarding the effective-
ness, costs and cost-effectiveness of treatment regimens in this patient group is essential for
clinical practice.
Costs of potential antibiotic resistance among both the patients’ intestinal flora and the
environment [26, 27] were not included in our evaluation. If these costs could have been taken
into account, the longer-term treatment regimens likely would have been less favorable in
terms of costs and cost-effectiveness compared to the shorter-term treatment. Antibiotic resis-
tance is a growing global threat, which has been estimated to cause 23,000 deaths and $55
Fig 3. a. Base case analysis: Nearest available observation imputation. b. Best-case imputation scenario. c. Worst-case
imputation scenario.
https://doi.org/10.1371/journal.pone.0195260.g003
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billion of healthcare costs and productivity losses each year in the United States [28]. In
Europe, these numbers were estimated to be 25,000 deaths and €1.5 billion yearly [28]. Since
antibiotic resistance is directly related to volumes of antibiotic treatment and since resistance
of both first-line and last-resort antibiotics is increasing rapidly, ineffective and even poten-
tially harmful treatment with antibiotics should be prevented.
Conclusions
From a societal perspective, the longer-term treatments of ceftriaxone combined with doxycy-
cline or with clarithromycin and hydroxychloroquine were as costly, effective and cost-effec-
tive as shorter-term treatment with ceftriaxone only in patients with persistent symptoms
attributed to Lyme disease after one year of follow-up. Taking into account the growing con-
cern to antibiotic resistance because of unnecessary use, the shorter-term provision of antibiot-
ics should be preferred.
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